BioSpace News Archive

- Record revenues in 2021 of $15.6 million versus $6.1 million in 2020 - Continued progress of strategic agreement with AbbVie to develop dermal and soft tissue filler products using CollPlant’s rhCollagen - Company to advance 3D bioprinted regenerative breast implant program with launch of large animal study expected in Q2 - Strong balance sheet with $43.3 million cash position, as of December 31, 2021 [24

[24-March-2022] First two cohorts indicate pelareorep in combination with paclitaxel was well-tolerated with no new safety signals observed to date Trial is designed to satisfy regulatory requirements and accelerate pelareorep’s development in large and rapidly growing pharmaceutical markets, including China , Hong Kong , Macau , Taiwan , Singapore , and South Korea Final cohort’s

Creyon Bio, Inc. announced today that David Dimmock , M.D., has joined the company as Chief Medical Officer.

Verastem Oncology today announced that Channing Der, PhD, has been appointed to its Scientific Advisory Board.

Taysha Gene Therapies, Inc. today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2021, and host a corporate update conference call and webcast on Thursday, March 31, 2022, at 8:00 AM Eastern Time.

Moderna today announced clinical and program updates demonstrating expansion and advancement of its mRNA pipeline.

Dante Labs announces the establishment of the first of its Medical Genomics Boards, strengthening the Company’s mission and research activity in this new frontier of healthcare, using genomics to promote prevention and treatment.

Milestone Pharmaceuticals Inc. today reported financial results for the fourth quarter and year ended December 31, 2021.

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), today announced it has received conditional approval from the Institutional Review Board (IRB) for its multi-site Phase 2b smoking cessation trial.

Stealth BioTherapeutics Corp announced today the upcoming presentation of new data at The Association for Research in Vision and Ophthalmology (2022) Annual Meeting.